Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.57 |
| ▸ | BRD2 | P25440 | 7/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217255 | 0.88 | BRD4 (0.55) | BRD4BRD2CREBBPFFAR1MAP4K4 | |
| SCHEMBL28047388 | 0.84 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL16675743 | 0.84 | BRD4 (0.58) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL25975868 | 0.83 | BRD4 (0.59) | BRD4BRD2CREBBPBRD3 | |
| SCHEMBL12881340 | 0.83 | BRD4 (0.59) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL12866840 | 0.82 | BRD4 (0.57) | BRD4BRD2CREBBPFFAR1MAP4K4 | |
| SCHEMBL3340053 | 0.80 | BRD4 (0.52) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL22775611 | 0.80 | BRD4 (0.60) | BRD4BRD2CREBBPFFAR1BRD3 | |
| SCHEMBL3338755 | 0.80 | HTR7 (0.62) | BRD4BRD2CREBBPFFAR1 | |
| SCHEMBL980536 | 0.79 | MAP4K4 (0.76) | BRD4BRD2CREBBPMAP4K4BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, SSTR5, FFAR3 | BRD4 3197/4885BRD2 3694/4885CREBBP 3270/4885 |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | BRD4 1322/4885BRD2 2999/4885CREBBP 1092/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | BRD4 1322/4885BRD2 2999/4885CREBBP 1092/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | BRD4 3425/4885BRD2 3903/4885CREBBP 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.